The purpose of the study is to determine whether lanabecestat can be safely prescribed in participants with kidney impairment without a dose adjustment. Participants will be on study for up to 6 weeks; this includes a 2-week screening and a follow-up about 10 days after final drug administration.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Administered orally
Administered intravenously. Administration is at investigator's discretion in participants with severe renal impairment.
Orange County Research Center
Tustin, California, United States
Clinical Pharmacology of Miami
Miami, Florida, United States
Orlando Clinical Research Ctr.
Orlando, Florida, United States
Pharmacokinetics (PK): Area Under The Concentration Versus Time Curve From Zero To Infinity (AUC[0-∞]) for Lanabecestat
PK: AUC(0-∞) for Lanabecestat
Time frame: Baseline through 168 hours after the administration of study drug
PK: Maximum Observed Drug Concentration (Cmax) of Lanabecestat
PK: Cmax of Lanabecestat
Time frame: Baseline through 168 hours after the administration of study drug
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.